MedTrace Logo

Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex

NCT03284164 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-06-06

No results posted yet for this study

Summary

This is a Phase 1 study to investigate the effects of Renal Impairment on the pharmacokinetics of Tenofovir exalidex

Conditions

  • Renal Impairment

Interventions

DRUG

Tenofovir Exalidex (TXL)

Drug: Tenofovir Exalidex (TXL)

Sponsors & Collaborators

  • ContraVir Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • John Sullivan-Bolyai, MD, MPH · ContraVir Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-28
Primary Completion
2018-01-17
Completion
2018-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03284164 on ClinicalTrials.gov